SCHEMBL4364274

SCHEMBL4364274

COC(=O)c1ccc(OCCc2ccc(Cl)cc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.66
RAB9A P51151 3/20 0.65
NPC1 O15118 3/20 0.65
MAOB P27338 3/20 0.56
MAOA P21397 2/20 0.56
KMT2A Q03164 3/20 0.55
ATM Q13315 1/20 0.55
CYP4A11 Q02928 2/20 0.53
MEN1 O00255 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PPARD Q03181 2/20 0.52
PPARA Q07869 2/20 0.52
PPARG P37231 1/20 0.52
CYP4F2 P78329 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
NR4A2 P43354 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14967260 0.87 MAPT (0.68) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL9038241 0.87 MAPT (0.68) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL14966315 0.87 MAPT (0.68) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL834524 0.85 MAPT (0.66) MAPTRAB9ANPC1MAOBKMT2A
SCHEMBL4361298 0.85 MAPT (0.77) MAPTRAB9ANPC1KMT2AMEN1
SCHEMBL5392156 0.85 MAPT (0.77) MAPTRAB9ANPC1KMT2ACYP4A11
SCHEMBL1283804 0.85 MAOB (0.72) MAPTMAOBMAOAKMT2AATM
SCHEMBL11218725 0.85 NPC1 (0.86) MAPTRAB9ANPC1MAOBMAOA
SCHEMBL4374627 0.83 NR4A2 (0.71) MAOBMAOAPPARDPPARAPPARG
SCHEMBL14967039 0.83 MAPT (0.62) MAPTRAB9ANPC1KMT2ACYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1908466-B1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO CO LTD (JP) 2014-02-19 EP disclosed
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 MAPT 3124/4885RAB9A 1479/4885NPC1 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.